Optovue AutoFusion
(RIGHT)
BOC Instruments has released AutoFusion – Optovue’s latest optical coherence tomography (OCT) device. This dual modality integrated OCT and fundus camera is simple to use, with a fully automated, streamlined operation and 3D auto tracking. It automatically aligns, focuses, tracks and captures with a single tap. The AutoFusion OCT is compact with an integrated PC and a tiltable LCD touch screen. It delivers high-resolution OCT images and 12-megapixel true colour retinal photos.
Features include comprehensive retinal, glaucoma, anterior and pachymetry analysis reports, as well as optic nerve and macular analysis from a single 3D wide scan. 3D imaging includes progressive Early Treatment Diabetic Retinopathy Study (ETDRS) thickness maps, and ganglion cell complex analysis. Optic nerve head (ONH) scanning provides progressive retinal nerve fibre layer and ONH parameter evaluation. Scan options include 5-line, cross, wide line, radial, corneal/anterior scans including pachymetry maps and angles. Trend analysis reports highlight structural changes and detailed quantitative assessment.
BOC Instruments supplies a range of OCT models to suit requirements and budget. Current Optovue OCT models are the AutoFusion, i-Scan80, i-Vue80, Solix Essential, and Solix FullRange with optional corneal topography functions.
Topcon Triton2 OCT
(LEFT)
The Topcon Triton2 is a next-generation multimodal swept-source optical coherence tomography (OCT) device that delivers high-density, deep-penetration imaging with impressive clinical versatility. With 1,050 nm wavelength and high-speed scanning, it offers clear visualisation of retinal and choroidal structures, even through media opacities, reducing motion artefacts and minimising rescans. Triton2 combines true-colour fundus imaging with innovative slit-scan technology for small pupils, plus optional wide-field OCT/OCT- angiography up to 21 mm for comprehensive retinal assessment. Powered by Imagenet7 with Smart Denoise, it enhances image quality, quantitative mapping, and follow-up comparisons. Features such as the Hood Report support glaucoma diagnosis, while optional anterior segment imaging broadens diagnostic capability and streamlines workflow.
M ACU L A R D I SE A SE I SSU E
Retimax by CSO
(RIGHT)
Early functional change in macular disease often precedes visible structural damage. Retimax enables clinicians to detect these subtle alterations through objective electrophysiological testing, including multifocal electroretinogram, pattern electroretinogram, and visual evoked potentials testing. Published clinical studies have shown that biofeedback training with Retimax can significantly improve best-corrected visual acuity, contrast sensitivity and fixation stability in patients with macular degeneration, while also enhancing reading performance and quality of life.
For practices focused on proactive care, the real advantage lies in earlier detection and intervention – identifying macular dysfunction before optical coherence tomography changes become pronounced. This allows timely referral, closer monitoring, and improved patient outcomes. By combining diagnostic precision with evidence-based visual rehabilitation, Retimax positions practices at the forefront of functional retinal assessment and modern low-vision management.
Spectralis
(RIGHT)
Spectralis is a multimodal retinal imaging platform designed to support the diagnosis and monitoring of macular disease. Confocal scanning laser ophthalmoscopy (cSLO), combined with high-resolution spectral-domain optical coherence tomography (OCT), enables simultaneous fundus and cross-sectional imaging with precise point-to-point correlation, helping clinicians visualise retinal microstructure in detail.
The Shift technology allows OCT scan speeds to be adapted to clinical needs: high- sensitivity 20 kHz scanning improves image quality in difficult-to-image eyes with media opacities, while 125 kHz scanning is optimised for OCT angiography to evaluate macular microvasculature. BluePeak fundus autofluorescence combined with OCT is widely used to assess and monitor geographic atrophy progression. TruTrack active eye tracking, ART image averaging, and AutoRescan support high-quality images and precise follow up for monitoring macular disease over time.